Immunopathogenesis and treatment of cytokine storm in COVID-19
Kim J, Lee J, Yang J, Lee K, Effenberger M, Szpirt W, Kronbichler A, Shin J. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 2021, 11: 316-329. PMID: 33391477, PMCID: PMC7681075, DOI: 10.7150/thno.49713.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory AgentsAntibodies, Monoclonal, HumanizedAzetidinesClinical Trials as TopicCOVID-19COVID-19 Drug TreatmentCytokine Release SyndromeCytokinesHumansImmunosuppressive AgentsInterleukin 1 Receptor Antagonist ProteinJanus KinasesPurinesPyrazolesSARS-CoV-2Severity of Illness IndexSignal TransductionSTAT Transcription FactorsSulfonamidesTreatment OutcomeConceptsSevere COVID-19Cytokine stormCytokine storm associated with COVID-19Development of cytokine stormAcute respiratory distress syndromeTreatment of cytokine stormCytokine release syndromeCytokine-targeted therapiesRespiratory distress syndromeExtracorporeal cytokine removalMultiple organ failureSystemic hyper-inflammationEarly stage of COVID-19 infectionType 1 IFNAnti-inflammatory therapyAnti-inflammatory treatmentCOVID-19 cytokine stormPotential therapeutic roleExcessive immune reactionsSevere coronavirus diseaseStage of COVID-19 infectionHemophagocytic lymphohistiocytosisDistress syndromeOrgan failureCOVID-19 infection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply